{
    "clinical_study": {
        "@rank": "156213", 
        "arm_group": [
            {
                "arm_group_label": "Day 1 MRI with low dose vaccine", 
                "arm_group_type": "Experimental", 
                "description": "DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course."
            }, 
            {
                "arm_group_label": "Day 3 MRI with low dose vaccine", 
                "arm_group_type": "Experimental", 
                "description": "DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course."
            }, 
            {
                "arm_group_label": "Day 1 MRI with high dose vaccine", 
                "arm_group_type": "Experimental", 
                "description": "DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course."
            }, 
            {
                "arm_group_label": "Day 3 MRI with high dose vaccine", 
                "arm_group_type": "Experimental", 
                "description": "DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and feasibility MRI tracking of a vaccine produced from\n      a persons cancer cells injected intradermally once a day for 3 consecutive days. One of the\n      daily doses will contain a chemical that can be detected by an MRI. That will be either the\n      1st or 3rd day of the 3 day course. On that day MRI scans will be performed 6 and 24 hours\n      after the injection on that day. Patients may be able to receive booster doses every 1-2\n      months"
        }, 
        "brief_title": "Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Colorectal Neoplasms", 
            "Colorectal Cancer", 
            "Colorectal Carcinoma", 
            "Colorectal Tumors", 
            "Neoplasms, Colorectal"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "STUDY EVALUATIONS\n\n        -  Pre-Vaccination\n\n             -  Complete physical examination (with ECOG performance status (PS), medical history,\n                weight, height, and BSA); the exact size and location of all tumor lesions will be\n                noted in the flow sheet, documented in the text note, and by photographic and/or\n                radiologic means\n\n             -  CEA levels in the blood (as a tumor marker)\n\n             -  Women of childbearing potential will have a serum beta-HCG pregnancy test\n\n             -  Anti-HIV, HbsAg and Anti-HCV\n\n             -  CBC, platelet, differential\n\n             -  Comprehensive metabolic panel (CMP) including: glucose, BUN, creatinine, sodium,\n                potassium, Cl, CO2, calcium, total protein, albumin, alkaline phosphatase, AST,\n                ALT, total bilirubin\n\n             -  PT/PTT testing\n\n             -  Electrocardiogram (EKG), if indicated\n\n             -  Radiologic imaging to evaluate the status of disease may be performed as a part of\n                routine care.\n\n             -  Leukapheresis\n\n             -  Dendritic cell vaccine preparation\n\n        -  Procedures during priming vaccination (Days 1 to 3)\n\n             -  Complete physical examination (with PS and weight)\n\n             -  19F/1H MRI scanning on day of vaccination, 6 hrs (\u00b11 hour) and 24 hrs (\u00b14 hour)\n                post-injection.\n\n             -  Blood for in vitro assays, before first i.d. administration on day 1 (baseline)\n                and after the last i.d. administration on day 3\n\n             -  DTH tests: administration on day 1 and readout on day 3\n\n             -  Biopsy of the DTH site can be performed in any subject who consented to such\n                biopsy, at the discretion of the investigator/sub-investigator (Day 3 only, based\n                on readout)\n\n        -  Procedures on Day 15\n\n             -  Complete physical examination (with ECOG PS and weight)\n\n             -  CBC, platelet, differential\n\n             -  Blood for in vitro assays\n\n        -  Procedures during booster courses (Days 36 to 38, 64 to 66, and 91 to 93)\n\n             -  Complete physical examination (with PS and weight) on the 1st day of each 3 day\n                course (Days 36, 64, and 91)\n\n             -  CBC, platelet, differential on the 1st day of each 3 day course (Days 36, 64, and\n                91)\n\n             -  Comprehensive metabolic panel (CMP) including: glucose, BUN, creatinine, sodium,\n                potassium, Cl, CO2, calcium, total protein, albumin, alkaline phosphatase, AST,\n                ALT, total bilirubin on the 1st day of each 3 day course (Days 36, 64, and 91)\n\n             -  DTH tests: administration on 1st day and readout on 3rd day during 2nd and 3rd\n                booster courses (Administration days 64 and 91, readout days 66 and 93)\n\n             -  Biopsy of the DTH site can be performed in any subject who consented to such\n                biopsy, at the discretion of the investigator/sub-investigator (3rd day of 3 day\n                course, based on readout of DTH test)\n\n             -  Blood for in vitro assays (1st and 3rd day of each 3 day course)\n\n        -  Procedures on Day 105\n\n             -  Complete physical examination (with ECOG PS and weight)\n\n             -  CEA levels in the blood (as a tumor marker)\n\n             -  CBC, platelet, differential\n\n             -  Comprehensive metabolic panel (CMP) including: glucose, BUN, creatinine, sodium,\n                potassium, Cl, CO2, calcium, total protein, albumin, alkaline phosphatase, AST,\n                ALT, total bilirubin\n\n             -  Radiologic imaging to evaluate the status of disease may be performed as a part of\n                routine care\n\n             -  Photography\n\n        -  Long term follow-up The subjects with lack of disease progression at 6 months after the\n           last vaccination will be monitored for the disease free survival and overall survival.\n           Subjects may be contacted every 3 months within the first three years after study\n           intervention, every six months until year 5, and annually afterwards. In lieu of direct\n           contact a medical record review may be performed to obtain the data for these time\n           points for disease progression and/or survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have adequate tumor tissue from surgery, performed as part of their\n             conventional care.\n\n          -  No chemotherapy, radiotherapy, major surgery, or biologic therapy for their\n             malignancy in the 2 weeks prior to vaccine administration and they must have\n             recovered from all side effects.\n\n          -  An ECOG performance status of 0, 1, or 2.\n\n          -  Age equal to 18 years or older.\n\n          -  Blood tests:\n\n               -  Platelet counts greater than 80,000 (platelet count, hematocrit, and WBC will be\n                  re-evaluated within 2 weeks prior to leukapheresis)\n\n               -  Hematocrit > 27.0\n\n               -  White blood count > 2000/\u00b5L\n\n               -  Creatinine less than or equal to 2 X ULN\n\n          -  Aware of the neoplastic nature of his/her illness, the experimental nature of the\n             study intervention, alternative treatments, potential benefits and risks, and willing\n             to sign a written informed consent document.\n\n        Exclusion Criteria:\n\n          -  Subjects currently treated with systemic immunosuppressive agents, including\n             steroids, are ineligible until 2 weeks after removal from immunosuppressive\n             treatment. Subjects on maintenance steroids because of adrenal insufficiency are\n             eligible.\n\n          -  Subjects with total bilirubin greater than 2 X ULN.\n\n          -  Subjects with uncontrolled pain.\n\n          -  Subjects with active autoimmune disease, positive serology for HIV, HBV, or HCV.\n             (Hypothyroidism is allowed.)\n\n          -  Subjects who are allergic to or develop an allergy to heparin.\n\n          -  Subjects who are pregnant.\n\n          -  Subjects who have sensitivity to drugs that provide local anesthesia.\n\n          -  Subjects who have medical contraindications for MRI. Such contraindications include:\n\n               -  Electrical implants such as cardiac pacemakers or perfusion pumps\n\n               -  Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,\n                  artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos\n                  near the eye or steel implants\n\n               -  Ferromagnetic objects such as jewelry or metal clips in clothing\n\n               -  Pre-existing medical conditions, including claustrophobic reactions, the\n                  likelihood of developing a seizure or any greater than normal potential for\n                  cardiac arrest"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671592", 
            "org_study_id": "10-052", 
            "secondary_id": "R01CA134633"
        }, 
        "intervention": {
            "arm_group_label": [
                "Day 1 MRI with low dose vaccine", 
                "Day 3 MRI with low dose vaccine", 
                "Day 1 MRI with high dose vaccine", 
                "Day 3 MRI with high dose vaccine"
            ], 
            "description": "Alpha-type-1-polarized dendritic cells (\u03b1DC1) pulsed with apoptotic autologous tumor.", 
            "intervention_name": "DC Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cancer", 
            "colorectal", 
            "tumor", 
            "neoplasms", 
            "carcinoma", 
            "vaccine"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15232"
                }, 
                "name": "UPMC Hillman Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety and Feasibility Evaluation of the MRI-based Tracking of Alpha-type-1 Dendritic Cell Vaccines in Patients With Colorectal Cancer", 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "David L. Bartlett, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Adverse events from the labeled DC vaccine", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Ability to track the labeled DC vaccine by MRI", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671592"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Pawel Kalinski", 
            "investigator_title": "Professor of Surgery", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Effectiveness of DC accumulation may be correlated with their effectiveness in inducing immune responses as measured by:\nIncrease in the magnitude in the DTH response to: A) autologous tumor lysates (primary endpoint of efficacy); B) KLH; and c) saline (control); all injected intradermally.\nPeripheral blood CD8+ and CD4+ T cell responses against autologous tumor cells, using IFN\u03b3-ELISPOT readout.\nIn any HLA-A2+ subjects on the protocol, we may evaluate peripheral blood CD8+ T cell responses against CRC-related peptide epitopes present, using IFN ELISPOT as readout.", 
                "measure": "Comparative analysis of the effectiveness of lymph node accumulation of DC vaccines injected to resting versus pre-activated nodes (DCs injected on day 1 versus day 3 of the three day-long vaccination cycle.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "May assess the disease-free survival and overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Pawel Kalinski", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}